ProNAi Therapeutics Reports Second Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ProNAi Therapeutics (DNAI) Misses Q2 EPS by 5c
August 12, 2016 7:27 AM EDTProNAi Therapeutics (NASDAQ: DNAI) reported Q2 EPS of ($0.43), $0.05 worse than the analyst estimate of ($0.38).
At June 30, 2016, ProNAi had $130.6 million in cash and cash equivalents compared to $150.2 million in cash and cash equivalents at December 31, 2015.
For earnings history and earnings-related data on ProNAi Therapeutics (DNAI) click here.
... More